Abstract:Background It is shown that the postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) was associated with survival benefit in an elderly population. We aimed to analyze the feasibility and efficacy of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm) to IIIA (UICC TNM Classification of Malignant Tumours, 7th edition) NSCLC. Methods Elderly patients were randomly assigned to receive adjuvant chemotherapy for one year consisting of either alternate-day oral administration of S-1 (80 mg/m 2 /day) for 4 days a week (Arm A) or a daily oral administration of S-1 (80 mg/m 2 /day) for 14 consecutive days followed by 7-day rest (Arm B). The primary endpoint was feasibility (treatment completion rate), which was defined as the proportion of patients who completed the allocated intervention for 6 months with a relative dose intensity (RDI) of 70% or more. Results We enrolled 101 patients in which 97 patients received S-1 treatment. The treatment completion rate at 6 months was 69.4% in Arm A and 64.6% in Arm B ( p = 0.67). Treatment completion rate in Arm B tended to be lower compared to Arm A, as the treatment period becomes longer (at 9 and 12 months). RDI of S-1 at 12 months and completion of S-1 administration without dose reduction or postponement at 12 months was significantly better in Arm A than in Arm B ( p = 0.026 and p < 0.001, respectively). Among adverse events, anorexia, skin symptoms and lacrimation of any grade were significantly more frequent in Arm B compared with Arm A ( p = 0.0036, 0.023 and 0.031, respectively). The 5-year recurrence-free survival rates were 56.9% and 65.7% for Arm A and B, respectively ( p = 0.22). The 5-year overall survival rates were 68.6% and 82.0% for Arm A and B, respectively ( p = 0.11). Conclusion Although several adverse effects were less frequent in Arm A, both alternate-day and daily oral administrations of S-1 were demonstrated to be feasible in elderly patients with completely resected NSCLC. Trial registration Unique ID issued by UMIN: UMIN000007819 (Date of registration: Apr 25, 2012) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009128 . Trial ID issued by jRCT: jRCTs061180089 (Date of registration: Mar 22, 2019, for a shift toward a “specified clinical trial” based on Clinical Trials Act in Japan) https://jrct.niph.go.jp/en-latest-detail/jRCTs061180089 .

Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

Phase II Study of S-1 Plus Leucovorin (a New 1-Week Treatment Regimen Followed by a 1-Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China.

Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)—IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China

A Phase Iii Study of S-1 Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

EAST-LC: Randomized Controlled Phase III Trial of S-1 Versus Docetaxel (DOC) in Patients with Non-Small Cell Lung Cancer (NSCLC) Who Had Received a Platinum-Based Treatment: Results from Patient-Reported Outcomes (Pros)

A Phase Ib Study of SHR-1210 Plus Apatinib for Heavily Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients.

1805P Apatinib Combined with Irinotecan in the Treatment of Small Cell Lung Cancer: A Phase II, Single-Arm, Prospective Study

Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey

Phase Ⅱ trial of low dosage S-1 concurrent with radiotherapy in patients with locally advanced or recurrent pancreatic cancer

Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3

Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)